“It’s essentially a Viagra-like drug for women in that diminished desire or libido is the most common feminine sexual problem, like erectile dysfunction is in men,” says John Thorp, principal investigator for North America in the clinical trials. Studies have shown that the prevalence of hypoactive sexual desire disorder in the U.S. ranges from 9 percent to 26 percent of women, depending on age and menopausal status.

UNC CHAPEL HILL—A drug originally designed to fight depression has shown to increase sex drive in women with low libido.

The clinical trials of the drug flibanserin were the first ever to test a therapy that works at the level of the brain to enhance libido in women reporting low sexual desire, says John Thorp Jr., McAllister distinguished professor of obstetrics and gynecology at the University of North Carolina at Chapel Hill School of Medicine. He is also principal investigator for North America in the studies.

“Flibanserin was a poor antidepressant,” Thorp says. “However, astute observers noted that it increased libido in laboratory animals and human subjects. So, we conducted multiple clinical trials and the women in our studies who took it for hypoactive sexual desire disorder reported significant improvements in sexual desire and satisfactory sexual experiences.

“It’s essentially a Viagra-like drug for women in that diminished desire or libido is the most common feminine sexual problem, like erectile dysfunction is in men,” Thorp adds.

Studies have shown that the prevalence of hypoactive sexual desire disorder in the U.S. ranges from 9 percent to 26 percent of women, depending on age and menopausal status. Flibanserin is currently an investigational drug and is available only to women taking part in clinical trials.

The results reported here were presented Nov. 16 at the Congress of the European Society for Sexual Medicine in Lyon, France. The presentation was given by Elaine Jolly, overall principal investigator and a professor at the University of Ottawa in Canada.

Jolly, Thorp, and colleagues pooled data from four clinical trials of flibanserin conducted in the United State, Canada, and Europe. A total of 1,946 pre-menopausal women ages 18 and older were randomized to receive either flibanserin or placebo for 24 weeks, with 4 weeks of pre-treatment baseline measurement and 4 weeks of post-treatment follow-up.

Initially, four different dosing regimens were used in the trials: 25 milligrams twice a day, 50 milligrams once a day at bedtime, 50 milligrams twice a day, and 100 milligrams once a day at bedtime.

The dosing regimens totaling 50 milligrams a day were not effective while the regimens totaling 100 milligrams were. So, the results being reported are from only three of the four trials and are based on the 100 milligrams once a day dosing regimen only.

The trials measured mean changes from baseline on a number of variables as reported by the women each week, including number of satisfying sexual events and electronic diary desire score.

The researchers concluded that treatment with 100 milligrams of flibanserin once a day was associated with significant improvements versus placebo.

“These results point to a novel approach to pharmacologic treatment of the sexual problem that plagues reproductive age women the most, and may over time prove to be an effective treatment without the side effects of androgen replacement therapy, which is the only treatment currently available,” Thorp notes.

The trials were funded by Boehringer Ingelheim Pharmaceuticals, the manufacturer of flibanserin.

UNC at Chapel Hill medical news: www.unchealthcare.org/site/newsroom